Skip to main content
OpenTrials
Completed

NCT Number: NCT00097123

RCT of Misoprostol for Postpartum Hemorrhage in India

Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

KLE Society's Jawaharlal Nehru Medical College

Belagavi, Karnataka, 590 010, India

About this study

Despite existing knowledge of ways to effectively treat postpartum hemorrhage (PPH), lack of resources in rural India has impeded improvement in rates of maternal mortality and morbidity. Most births take place at home, and local auxiliary nurse midwives are not trained or certified to administer injectable uterotonics. Reduction in postpartum hemorrhage may decrease other adverse maternal outcomes such as the need for additional uterotonic agents, blood transfusion, surgical intervention or death. The main hypothesis of the study is that misoprostol administered orally during the third stage of labor will significantly reduce the incidence of acute postpartum hemorrhage. The advantages of misoprostol are: that it is relatively inexpensive, is an oral preparation of 600 mcg with a long shelf life, and does not require refrigeration. One thousand six hundred women giving birth in selected sites in Belgaum District, Karnataka, India will be randomly assigned to misoprostol or placebo. The primary outcome is the incidence of acute postpartum hemorrhage; secondary outcomes include incidence of delayed postpartum hemorrhage and secondary infection; transport to higher-level facility; use of uterotonic agents; blood transfusion; and maternal mortality for 42 days. A nested case-control analysis of women who experience acute severe postpartum hemorrhage, compared to women who do not, will identify socioeconomic, behavioral, cultural, and systems factors associated with postpartum hemorrhage. For purposes of this study, acute PPH is defined as blood loss equal to or greater than 500 ml within 2 hours of delivery and acute severe PPH as blood loss equal to or greater than 1000 ml within 2 hours of delivery.

The sample size was based on a decrease of 50% PPH in the treated versus the control group; 20% rate of non-compliance, power of 96%, and a two-tailed type I error of 0.05

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age equal to or greater than 28 weeks pregnant
  • Planning to deliver at home or at a sub-center in the Belgaum District, Karnataka India
  • Anticipating a spontaneous vaginal delivery
  • Ability and willingness to provide informed consent

Exclusion criteria

  • Previous caesarian section
  • Scheduled for caesarian section
  • Hemoglobin level less than 8 Gms%
  • Episodes of antepartum bleeding during the current pregnancy
  • Blood pressure more than 140 mm of Hg systolic and 90 mm of Hg diastolic
  • In active labor and not previously screened, recruited, and consented
  • Absence of fetal heart sounds
  • Multiple pregnancy
  • Known history of bronchial asthma
  • Prior enrollment in this study during a previous pregnancy
  • History of complications (ante/postpartum hemorrhage/retained placenta/ acute inversion of uterus) during a previous pregnancy
  • High risk conditions including: diabetes, cardiac ailments, seizures, placenta previa or anticipated breech delivery.
  • Receiving injectable medicine at time of delivery

Treatment and study plan

Misoprostol

Drug

Primary outcomes

  1. Incidence of acute postpartum hemorrhage: blood loss ≥ 500 ml within two hours of delivery

Secondary outcomes

  1. Incidence of delayed postpartum hemorrhage and secondary infection (lower abdominal pain, fever and foul discharge)

  2. Transport to higher-level medical facility

  3. Use of uterotonic agents

  4. Blood transfusion

  5. Surgical intervention including curettage, vacuum aspiration for retained placental tissue or hysterectomy

  6. Maternal mortality for 42 days

Sponsors and collaborators

Lead sponsor

NICHD Global Network for Women's and Children's Health

Network

Collaborators

  • Bill and Melinda Gates Foundation
  • Fogarty International Center of the National Institute of Health
  • Global Network for Women's and Children's Health Research
  • Jawaharlal Nehru Medical College
  • National Cancer Institute (NCI)
  • National Center for Complementary and Integrative Health (NCCIH)
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • RTI International
  • University of Missouri-Columbia

Registry information

Important dates

Study start
2002
Primary completion
2005
Study completion
2005
First posted
Nov 18, 2004
Registry last updated
Jul 31, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.